Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Althoff MJ, Nayak RC, Hegde S, Wellendorf AM, Bohan B, Filippi M-, et al. Yap1-Scribble polarization is required for hematopoietic stem cell division and fate. Blood. 2020;136(16):1824-1836.

Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440-459.

Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4(19):4640-4647.

Siddiqui MT. Serous cavity fluids: Momentum, molecules, markers… and more! Cancer Cytopathol. 2020;128(6):381-383.

Soderquist CR, Patel N, Murty VV, Betman S, Aggarwal N, Young KH, et al. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica. 2020;105(7):1895-1906.

Laurence J, J Mulvey J, Seshadri M, Racanelli A, Harp J, Schenck EJ, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.

Day W, Gabriel C, Kelly RE, Magro CM, Williams JV, Werner A, et al. Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review. Rheumatol Int. 2020;40(11):1883-1890.

Ma LX, Craig KM, Mosquera JM, Robinson BD, Scherr DS, Del Pizzo J, et al. Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience. Cancer Treat Res Commun. 2020;25:100209.

Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PA, et al. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. medRxiv. 2020.

Itkonen HM, Poulose N, Steele RE, Martin SE, Levine ZG, Duveau DY, et al. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. Mol Cancer Res. 2020;18(10):1512-1521.